Tag: gastroparesis drugs market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Respules Market?

The market for gastroparesis drugs has seen substantial growth in the past few years. It’s expected to increase from $5.39 billion in 2024 to $5.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Reasons for the growth in the historical period include the side effects associated with current treatments, research into gastrointestinal motility, clinical necessity, support from patient advocacy groups, and assistance from regulatory bodies.

In the forthcoming years, the market size for gastroparesis drugs is anticipated to experience robust expansion, set to reach “$7.04 billion by 2029“, progressing at a compound annual growth rate (CAGR) of “5.4%“. The predicted growth during this estimated period can be credited to factors such as the surging prevalence of diabetes, an aging demographic, heightened awareness and diagnosis procedures, augmentation in healthcare spending as well as governmental and private-sector investment. Foreseen trends within this period comprise advancements in the field of gastroenterology, progress in diagnostic methodologies, technological innovations, funding for research, and cooperative research initiatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Factor Is Shaping The Future Of The Respules Market?

An increase in respiratory ailments is anticipated to spur the respules market’s expansion. These respiratory diseases include lung conditions and sicknesses such as tuberculosis, lung cancer, pulmonary hypertension, mesothelioma, cystic fibrosis, emphysema, and asthma. Respules are used to manage a variety of respiratory diseases, such as bronchial asthma, emphysema, spasmodic stenosis, and irregular bronchial mucus production. For instance, the Australian Bureau of Statistics, a governmental agency in Australia, reported in December 2023 that in 2022, 2.5% of the populace (638,100 individuals) suffered from COPD, showing similar prevalence amongst males (2.4%) and females (2.6%). Daily smokers were significantly more prone to COPD (8.1%) in comparison to former smokers (4.4%) and those who had never smoked (1.6%). Consequently, the increasing prevalence of respiratory disorders is fueling the expansion of the respules market.

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Emerging Trends And Strategic Shifts Are Shaping The Respules Market?

Leading enterprises within the realm of the gastroparesis drugs market are pivoting towards the launch of inventive drugs like Gimoti (metoclopramide) nasal spray to establish an advantageous position within the industry. Gimoti (metoclopramide) nasal spray functions as therapeutic medication for gastroparesis symptoms in adults by boosting stomach clearing through amplified gastrointestinal mobility. This drug bypasses the gastrointestinal passage and infiltrates into the bloodstream directly via nasal mucosa. Evoke Pharma Inc., an American pharmaceutical firm, proclaimed in April 2022 that the U.S. Food and Drug Administration (FDA) allotted fresh drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity under the Hatch-Waxman Act bestows Evoke the exclusive privilege to market the drug for a period of three years from the initial approval date, protecting it from competition by generics.

Which Companies Hold The Largest Market Share In The Respules Sector?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How Does Regional Performance Compare Across The Respules Industry?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Estimated Market Size of the Gastroparesis Drugs Market In 2029?#_x000D_

The market size for gastroparesis medications has seen substantial growth in recent times. The market is projected to expand from a value of $5.39 billion in 2024 to around $5.7 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.7%. This growth in the past period is a result of various factors including the side effects of current treatments, research into gastrointestinal motility, clinical demand, the push from patient advocacy groups, and regulatory backing._x000D_

_x000D_

Anticipated to witness substantial growth in the coming years, the market size of gastroparesis drugs is projected to reach $7.04 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. Factors leading to growth during this forecast period include escalating incidences of diabetes, an ageing demographic, heightened awareness and diagnosis, growth in healthcare spending, alongside government and private sector funding. The forecast period will also see significant trends such as progress in the field of gastroenterology, enhancements in diagnostic methodologies, technological innovation, backed by research investment and joint research endeavours._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp_x000D_

_x000D_

#What External and Internal Drivers Are Contributing to the Growth of theGastroparesis Drugs Market?#_x000D_

Gastroparesis drug market growth is expected to be fueled by the increasing cases of diabetes. High blood sugar levels due to either insufficient insulin production or insulin’s ineffective utilization are the highlights of this ongoing health crisis named diabetes. The surge in diabetes cases is a result of inactive lifestyles, unhealthy eating habits, genetic factors, urbanization, and aging population. This is further intensified by inadequate healthcare and the growing global obesity figures. It’s common practice for doctors to prescribe gastroparesis medications for diabetics experiencing symptoms such as nausea, vomiting, and delayed gastric emptying; all are typical complications of diabetes affecting the gastrointestinal movement. The goal of these drugs is to boost gastric function, thereby improving the quality of life for those suffering from diabetes-induced gastroparesis. As an example, the Office for Health Improvement & Disparities, a government department based in the UK, reported in March 2024 that from March 2022 to March 2023, there was a 22% increase in the number of people with type 1 diabetes who were undergoing all eight recommended care processes. This figure was 21% for type 2 diabetes, while those accomplishing the target HbA1c levels increased to the highest-ever reported figure of 37.9%, as per the National Diabetes Audit (NDA). Consequently, the escalating cases of diabetes are pushing the growth of the gastroparesis drugs market._x000D_

_x000D_

#What Segment Types Define the Gastroparesis Drugs Market Structure?#_x000D_

The gastroparesis drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs_x000D_

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes_x000D_

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types_x000D_

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration_x000D_

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce_x000D_

_x000D_

Subsegments:_x000D_

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements_x000D_

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Gastroparesis Drugs Market?#_x000D_

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Gastroparesis Drugs Market?#_x000D_

Companies that are leading in the gastroparesis drugs market are prioritizing the development and introduction of novel medications, such as Gimoti (metoclopramide) nasal spray, in order to gain a strategic advantage. Gimoti (metoclopramide) nasal spray is a therapeutic drug used for treating gastroparesis symptoms in adults by enhancing the gastric emptying process through improved gastrointestinal function. The drug bypasses the gastrointestinal system and enters the bloodstream directly through the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., an American pharmaceutical firm, reported that the U.S. Food and Drug Administration (FDA) had bestowed new drug product exclusivity to GIMOTI (metoclopramide) nasal spray. This is exclusive marketing rights for three years starting from the approval date as per the Hatch-Waxman Act, safeguarding the product from any generic competition._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report_x000D_

_x000D_

#What Is the Definition of the Gastroparesis Drugs Market?#_x000D_

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the gastroparesis drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Gastroparesis Drugs Market, and What Factors Will Drive It?

In recent times, the market size for gastroparesis drugs has seen substantial growth. The market, which stood at $5.39 billion in 2024, is forecasted to increase to $5.73 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.3%. The observed growth in the past period is a result of various factors such as the side effects of current treatments, research in gastrointestinal motility, clinical demand, patient advocacy efforts, and regulatory backing.

The market size for gastroparesis drugs is predicted to experience a significant expansion in the coming years, reaching $7.2 billion by 2029 with a compound annual growth rate (CAGR) of 5.9%. This growth during the forecast period is attributed to factors such as the rising prevalence of diabetes, an aging population, increased awareness and diagnostic capabilities, growth in healthcare spending, and financial support from both governmental and private entities. The forecast period is also expected to be influenced by key trends including breakthroughs in gastroenterology, enhanced diagnostic methods, technological advances, increased funding for research, and cooperative research endeavors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Are the Core Market Drivers Propelling Growth in the Gastroparesis Drugs Industry?

The escalating incidents of diabetes are predicted to fuel the expansion of the gastroparesis drugs market in the future. Diabetes manifests as a continual health problem characterized by elevated blood sugar levels arising from insufficient insulin production or the body’s ineffectual use of insulin. The mounting incidents of diabetes can be attributed to inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, and an aging demographic, exacerbated by limited healthcare accessibility and the global rise in obesity rates. Gastroparesis medications are often administered to diabetic patients to mitigate symptoms such as nausea, vomiting, and slow gastric emptying, which are typical diabetes complications that affect the function of the gut. These treatments aim to enhance gastric activity and boost the quality of life for people suffering from diabetes-induced gastroparesis. For example, in March 2024, the Office for Health Improvement & Disparities, a governmental department based in the UK, reported that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes undergoing all eight suggested care processes climbed by 22%, and for type 2 diabetes, it escalated by 21%. Simultaneously, the percentage accomplishing target HbA1c levels advanced to 37.9%, a record high reported by the National Diabetes Audit (NDA). Consequently, the climbing incidents of diabetes are propelling the growth of the gastroparesis drugs market.

What Segment Types Define the Gastroparesis Drugs Market Structure?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Which Regions Are Driving the Next Phase of the Gastroparesis Drugs Market Growth?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Emerging Trends that Are Influencing the Gastroparesis Drugs Industry Evolution?

To gain an advantage in the gastroparesis drugs sector, leading corporations are focusing on the development and launch of innovative medicines like Gimoti (metoclopramide) nasal spray. This medication, which treats gastroparesis symptoms in adults by speeding up the emptying of the stomach through improved gastrointestinal motility, is absorbed directly into the bloodstream via the nasal mucosa, bypassing the gastrointestinal tract. For example, Evoke Pharma Inc., an American pharmaceutical firm, announced in April 2022 that it had secured new drug product exclusivity for GIMOTI (metoclopramide) nasal spray from the U.S. Food and Drug Administration (FDA). Under the Hatch-Waxman Act, this exclusivity grants Evoke sole marketing rights for the product for a period of three years from the initial authorization date, shielding it from generic market rivals.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

What Is the Definition of the Gastroparesis Drugs Market?

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theGastroparesis Drugs Market?

The growth of the gastroparesis drugs market is anticipated to be fueled by the escalating incidence of diabetes. Recognized as a chronic health concern characterized by elevated blood sugar levels, diabetes results from insufficient insulin production or the body’s poor response to insulin. Factors like inactive lifestyles, unhealthy eating habits, genetic factors, urban growth, and aging populations contribute to the rising trend of diabetes, augmented by restricted healthcare access and a global surge in obesity. Drugs for gastroparesis, a common complication in diabetic patients characterized by symptoms like nausea, vomiting, and tardy gastric emptying, are commonly prescribed. These drugs aim to enhance gastric function and improve life quality for those suffering from diabetes-related gastroparesis. As per the Office for Health Improvement & Disparities, a UK Government department, records from March 2022 to March 2023 show a marked rise of 22% and 21% in the percentage of individuals with type 1 and type 2 diabetes respectively, receiving all eight recommended care processes. Moreover, those achieving target HbA1c levels rose to the highest ever reported at 37.9%, according to the National Diabetes Audit (NDA). Consequently, the escalating incidence of diabetes is propelling the gastroparesis drugs market growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

#What is the Anticipated CAGR of theGastroparesis Drugs Market, and What Factors Will Drive It?

The market for gastroparesis drugs has seen robust growth in the past few years. The market size is predicted to expand from $5.39 billion in 2024 to $5.73 billion in 2025, witnessing a compound annual growth rate (CAGR) of 6.3%. This substantial growth during the historic period is due to factors such as the side effects of current treatment methods, research on gastrointestinal motility, clinical demand, patient advocacy, and regulatory backing.

The market size of drugs for gastroparesis is anticipated to witness robust growth in the upcoming years. By 2029, it’s projected to reach $7.2 billion, with a compound annual growth rate (CAGR) of 5.9%. The growth within this forecast period can be credited to factors like the rising cases of diabetes, an aging demographic, escalating awareness and diagnosis rates, an increase in healthcare spending and both government and private sector funding. Key trends expected in this forecast timeframe include developments in gastroenterology, enhanced diagnostic methodologies, technological breakthroughs, allocation of funds for research and combined research initiatives.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

What Key Market Trends and Innovations Are Shaping the Future of theGastroparesis Drugs Industry?

Leading players in the gastroparesis drugs industry are concentrating on the launch of groundbreaking medicines like Gimoti (metoclopramide) nasal spray to secure a competitive advantage. This drug is utilized to manage gastroparesis symptoms in adults by accelerating gastric emptying through enhanced gastrointestinal mobility. Unlike other treatments, it doesn’t pass through the digestive tract and is instead directly assimilated into the bloodstream via the nasal lining. As an example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, proclaimed the U.S. Food and Drug Administration (FDA) gave exclusivity for their new drug, GIMOTI (metoclopramide) nasal spray. With the protection afforded by the Hatch-Waxman Act, this exclusivity will shield the product from generic competitors for three years from its original approval, giving Evoke sole rights to its marketing.

Which Companies Are Leading the Charge in Expanding theGastroparesis Drugs Market Growth?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How is the Global Gastroparesis Drugs Market Segemented?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Which Geographics are Influencing the Growth of the Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2025, By The Business Research Company:

Fertility Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Gastrointestinal Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Gastrointestinal Bleeding Treatment Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Rapidly is the Gastroparesis Drugs Market Expected to Expand Between 2025 and 2034 Based on Current Trends?

Recent years have seen a significant growth in the market size of gastroparesis drugs. It is forecasted to increase from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR) of 6.3%. Factors such as the side effects of current treatments, research into gastrointestinal motility, clinical necessity, patient advocacy, and regulatory backing have all contributed to the growth throughout the historical period.

The market for gastroparesis drugs is projected to witness robust expansion in the upcoming years. The market is anticipated to reach $7.2 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.9%. Factors attributing to this growth over the forecast period are identified as escalating diabetes cases, the aging demographic, increased awareness and rates of diagnosis, a rise in healthcare spending, along with governmental and private investments. Key trends expected during the forecast period encompass developments in gastroenterology, enhanced diagnostic methods, technological progression, allocation of research funding, and joint research initiatives.

What Combination of Drivers Is Leading to Accelerated Growth in the Gastroparesis Drugs Market?

The escalating occurrence of diabetes is anticipated to fuel the expansion of the gastroparesis drugs market in the future. Diabetes is a chronic health problem characterized by elevated blood sugar levels, due to either insufficient insulin production or the body’s inefficient use of insulin. The rising occurrence of diabetes can be attributed to factors such as inactive lifestyles, unhealthy eating patterns, inheriting genes, urbanization and aging populations, amplified by insufficient healthcare access and growing global obesity rates. Patients with diabetes are often given gastroparesis drugs to mitigate complications like nausea, vomiting, and slower gastric emptying, which are common disturbances of gastrointestinal motility seen in diabetes. The aim of these drugs is to augment gastric function and improve lifestyle quality for people suffering from diabetes-induced gastroparesis. For instance, the Office for Health Improvement & Disparities, a government branch based in the UK, reported in March 2024 that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight advised care processes rose by 22%, and for those with type 2 diabetes, it increased by 21%. Moreover, the percentage of individuals achieving target HbA1c levels spiked to 37.9%, which is the highest value recorded by the National Diabetes Audit (NDA). Thus, the heightened occurrence of diabetes is augmenting growth in the gastroparesis drugs market.

Get Your Free Sample of the Global Gastroparesis Drugs Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Players Are Shaping the Future of the Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are:

• Amazon.com Inc._x000D_

• Alphabet Inc._x000D_

• Adobe Inc._x000D_

• Zalando SE_x000D_

• Farfetch Group Limited_x000D_

How Are the Latest Trends Influencing the Growth of the Gastroparesis Drugs Market?

Leading businesses in the gastroparesis drugs market are putting their efforts towards the introduction of inventive medications, such as Gimoti (metoclopramide) nasal spray, to acquire a beneficial position in the market. Gimoti (metoclopramide) nasal spray is a therapeutic drug designed to alleviate gastroparesis symptoms in adults by promoting better stomach emptying via improved gastrointestinal motility. This drug circumvents the gastrointestinal tract and gets absorbed directly into the bloodstream via the nasal mucosa. For instance, Evoke Pharma Inc., a pharmaceutical firm based in the United States, revealed in April 2022 that the U.S. Food and Drug Administration (FDA) conferred new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity endows Evoke with exclusive marketing privileges for three years from the initial approval date under the Hatch-Waxman Act, safeguarding the product from generic market competition.

Get Instant Access to the Global Gastroparesis Drugs Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How Are Market Segments in the Gastroparesis Drugs Industry Positioned for Long-Term Growth?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Regions Are At the Forefront of Gastroparesis Drugs Market Expansion?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Can We Define the Gastroparesis Drugs Market and Its Key Components?

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.

Browse Through More Similar Reports By The Business Research Company:

Fertility Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Gastrointestinal Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Gastrointestinal Bleeding Treatment Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: